quinuclidines has been researched along with azacitidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sallman, DA | 1 |
| Ades, L; Attalah, H; Berthon, C; Bève, B; Carpentier, AF; Chermat, F; Chevret, S; Cluzeau, T; Cuzzubbo, S; Fenaux, P; Komrokji, R; Lehmann-Che, J; Loschi, M; Madelaine, I; Miekoutima, E; Peterlin, P; Quesnel, B; Raffoux, E; Rahmé, R; Rauzy, OB; Recher, C; Sallman, DA; Sebert, M; Stamatoullas, A; Walter-Petrich, A; Willems, L | 1 |
| Cassinat, B; Diawara, Y; Fenaux, P; Giraudier, S; Maslah, N; Sebert, M | 1 |
1 trial(s) available for quinuclidines and azacitidine
| Article | Year |
|---|---|
Eprenetapopt Plus Azacitidine in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2021 |
2 other study(ies) available for quinuclidines and azacitidine
| Article | Year |
|---|---|
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2020 |
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured | 2021 |